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Editor’s key points
† Severe aortic stenosis is
associated with loss of
high-molecular-weight
von Willebrand factor
(vWF) multimers, but its
impact on perioperative
bleeding is unclear.
† In a prospective
observational study of 60
subjects undergoing
aortic valve replacement
for severe aortic stenosis,
vWF activity and
multimer structure were
measured.
† There was no association
between reduced
high-molecular-weight
vWF multimers and
postoperative blood loss.
† This could be due to rapid
recovery of vWF after
valve replacement.
Background. Severe aortic stenosis is associated with loss of the largest von Willebrand
factor (vWF) multimers, which could affect primary haemostasis. We hypothesized that
the altered multimer structure with the loss of the largest multimers increases
postoperative bleeding in patients undergoing aortic valve replacement.
Methods. We prospectively included 60 subjects with severe aortic stenosis. Before and
after aortic valve replacement, vWF antigen, activity, and multimer structure were
determined and platelet function was measured by impedance aggregometry. Blood loss
from mediastinal drainage and the use of blood and haemostatic products were
evaluated perioperatively.
Results. Before operation, the altered multimer structure was present in 48 subjects (80%).
Baseline characteristics and laboratory data were similar in all subjects. The median blood
loss after 6 h was 250 (105–400) and 145 (85–240) ml in the groups with the altered and
normal multimer structures, respectively (P¼0.182). After 24 h, the cumulative loss was 495
(270–650) and 375 (310–600) ml in the groups with the altered and normal multimer
structures, respectively (P¼0.713). Multivariable analysis revealed no significant influence
of multimer structure and platelet function on bleeding volumes after 6 and 24 h. After
24 h, there was no obvious difference in vWF antigen, activity, and multimer structure in
subjects with and without the altered multimer structure before operation or in subjects
with and without perioperative plasma transfusion.
Conclusions. The altered vWF multimer structure before operation was not associated with
increased bleeding after aortic valve replacement. Our findings might be explained by
perioperative release of vWF and rapid recovery of the largest vWF multimers.
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An association between aortic valve stenosis and gastrointes-
tinal bleeding (Heyde’s syndrome) was first reported in 1958.1
The haemorrhagic diathesis in patients with severe aortic
stenosis was explained by an acquired von Willebrand
disease (vWD) type 2A, which is characterized by the loss of
the largest (high-molecular-weight) multimers of von Wille-
brand factor (vWF) and decreased vWF-dependent platelet
adhesion and aggregation.2 3 The shear stress-dependent
cleavage of the largest vWF multimers by ADAMTS13 (a disin-
tegrin and metalloproteinase with a thrombospondin type
1 motif, member 13) is claimed to be responsible for the
laboratory findings similar to vWD 2A in patients with severe
aortic stenosis.4 vWF plays a pivotal role in primary haemo-
stasis as a ligand that bridges platelet GP Ib/IX and collagen
under high shear conditions, thereby inducing platelet adhe-
sion to the denuded vessel wall followed by platelet activation
and aggregation.5 vWF is present in plasma as high-, middle-,
and low-molecular-weight multimer forms. The largest
multimers are thought to be most important for primary
haemostasis and platelet activation.3 5 – 7
Several observational studies including more than 150
patients showed that loss of the largest vWF multimers
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was present in 33–92% of the patients depending on the
severity of aortic stenosis, detection method, and diagnosis
criteria used.8 – 11 In addition, several studies using different
platelet function analysers showed impaired platelet func-
tion associated with reduced levels of large vWF multimers
in patients with severe aortic stenosis.5 8 12 13 Aortic valve
replacement in affected patients induced long-lasting correc-
tion of bleeding diathesis and the recovery of vWF multimer
structure and platelet function within hours after surgery.5 8
12 14 Potentially, loss of the largest vWF multimers compro-
mises the capacity of primary haemostasis in patients under-
going aortic valve replacement.
The aim of this study was to investigate the effect of
altered vWF multimer structure on bleeding from mediastinal
drainage and transfusion requirements after aortic valve
replacement. We hypothesized that patients with the
altered vWF multimer structure have increased postoperative
bleeding due to impaired primary haemostasis.
Methods
Subjects
After approval by the local ethics committee (Ethikkommis-
sion beider Basel, Basel, Switzerland) and obtaining written
informed consent, we prospectively enrolled 67 consecutive
subjects from September 2008 until March 2010 at the
University Hospital Basel, Switzerland. Subjects were included
if they underwent surgical aortic valve replacement for
severe aortic valve stenosis, defined as calculated effective
orifice area (EOA) ≤1.0 cm2 or a mean pressure gradient
over the aortic valve of ≥50 mm Hg. Patients were not
included if they were under 18 yr of age or were not compe-
tent to give consent, if the surgical procedure was not
restricted to aortic valve replacement, if surgery included
the use of deep hypothermic cardiac arrest, or if they had
kidney failure (calculated creatinine clearance ,30 ml
min21) or elevated liver enzymes (more than twice the
upper normal level). According to the institutional practice,
patients were allowed to take aspirin (100 mg day21) and
clopidogrel (75 mg day21) until the day before surgery,
whereas coumarins were stopped at least 3 days before
surgery. Seven subjects were excluded from the analysis as
indicated in Figure 1, leaving 60 subjects in the study.
Routine laboratory tests including blood count and meas-
urement of international normalized ratio (INR), activated
partial thromboplastin time (aPTT), and fibrinogen concentra-
tion were performed on the morning of the day before surgery,
directly after arrival on the intensive care unit (ICU), and on the
morning of the first and the second day after surgery. Echocar-
diographic evaluation was performed during routine preopera-
tive evaluation. The mean and peak transvalvular pressure
gradients were calculated using the modified Bernoulli equa-
tion, and the EOA was calculated with the continuity equation.
Screening for haemorrhagic disorders
Bleeding symptoms were evaluated by use of a standardized
screening questionnaire adapted from those described by
Koscielny and colleagues15 and Tosetto and colleagues.16
Two authors (D.B. and S.D.-K.) blinded to other subject data
independently evaluated bleeding risk. Subjects were rated
as at ‘increased bleeding risk’ when there was (i) a haemor-
rhagic disorder within the last 24 months preceding surgery
or (ii) intake of clopidogrel until the day before surgery.17 18
Disagreement was resolved by consensus; agreement
between the two raters was 0.91 as evaluated by k statistics.
Blood collection and laboratory assays
Blood for study purposes was collected directly before
surgery and 24 h after the end of surgery into sodium
citrate tubes for vWF electrophoretic multimer analysis and
into hirudin tubes for platelet function analysis (Sarstedt
AG, Sevelen, Switzerland). Sodium citrate tubes were sent
to the central laboratory and immediately centrifuged to
obtain platelet-poor plasma, which was aliquoted and
frozen at 2708C for vWF analysis (MEDILYS Coagulation
Laboratory, Hamburg, Germany).
vWF antigen (vWF:Ag; in IU dl21) was measured immuno-
logically according to standard protocols on a Behring Coagu-
lation System analyser. vWF activity (in IU dl21) was
determined photometrically by ELISA and described as
collagen-binding capacity (vWF:CB).19 For multimer analysis,
vWF multimers were separated on low-resolution agarose
gels (1.2% agarose), blotted on a polyvinylidene difluoride
membrane, and detected using appropriate primary and
secondary antibodies and chemiluminescence as described
previously.9 20 Pre- and postoperative samples were analysed
in parallel on the same gel. Loss of the largest multimers
(defined as band 11 or higher, corresponding to a molecular
weight of 6000 kDa)20 and percentage of large multimers
were determined by the external coagulation laboratory
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n=67
Excluded n=7
Excluded n=1
Revision due to surgical bleeding n=1
Follow-up completed n=47
No follow-up n=13
Incorrect sample/sample volume
Refusal by the patient/
patient’s general practicioner
n=4
n=9
Surgery cancelled/postponed n=2
Surgery changed/additional surgery n=2
Died during surgery n=1
vWF multimer analysis not possible n=2
vWF/platelet function analysis n=60
Bleeding/transfusion analysis n=59
Fig 1 Flow chart for study inclusion, analysis, and follow-up.
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(MEDILYS), which was not involved in the study and was
blinded for all other study data.
In the pre- and postoperative blood samples, platelet
function analysis was performed using multiple electrode
aggregometry (MultiplateTM, Dynabite, Munich, Germany)
according to the manufacturer’s instructions by two experi-
enced members of the study team (M.G. and U.Z.) blinded
to all other study data. This system has been previously
described in detail.21 Briefly, 300 ml of hirudin-anticoagulated
whole blood was diluted with 300 ml of saline. After incuba-
tion at 378C, a platelet agonist was added to the test cell.
Subsequently, the impedance change, which is proportional
to the amount of activated platelets adhering to the
sensors, was continuously monitored for 6 min and trans-
formed to arbitrary ‘units’ (U). Platelets were activated by
thrombin receptor-activating peptide (TRAP)-6 (32 mM) in
the TRAP test, by collagen (3.2 mg ml21) in the COL test,
and by ristocetin (0.77 mg ml21) in the RISTO test.
Perioperative period and follow-up
Anticoagulation during cardiopulmonary bypass (CPB) was
performed by an initial 350 IU kg21 bolus of heparin and
additional doses to maintain activated clotting time .480
s. Antifibrinolytic therapy with a 30 mg kg21 bolus of tranex-
amic acid was administered to every subject at the beginning
of surgery. Heparin was neutralized with 1.5 mg protamine per
100 IU of the initial bolus according to institutional practice.
An additional bolus of protamine was administered when
activated clotting time was .110% of the preoperative value.
Erythrocyte concentrates and haemostatic products
including fresh-frozen plasma (FFP), platelet concentrates,
and fibrinogen concentrate (Haemocomplettanw, CSL Behring,
Switzerland) were administered at the discretion of direct care
providers (anaesthesiologist or intensivist) who were not
involved in the study. The study had no influence on the surgical
procedure or on haemostatic and transfusion management.
During the immediate postoperative course, blood loss
from mediastinal drainage after arrival on the ICU, 3, 6, 12,
24, and 36 h after surgery, was assessed and prospectively
recorded by the caregivers on the ICU, blinded to all other
study data. In addition, transfusion of erythrocyte concen-
trates and haemostatic products during surgery and hospital
stay was evaluated and also any additional surgery or
adverse event during the hospital stay.
The subject’s general practitioners were asked to collect
blood for vWF analysis during a routine follow-up visit. The
blood samples collected in the 3.8% sodium citrate tubes
were shipped at room temperature on the same day to
our hospital’s central laboratory. At the central laboratory,
samples were immediately processed and handled as
described above. No platelet aggregometry or echocardiog-
raphy was performed during follow-up.
Statistical analysis
The sample size calculation was based on preliminary data,
estimating that the altered vWF multimer structure was
present in 60% of the patients undergoing aortic valve
replacement, which is in agreement with recently published
studies.8 – 11 Assuming a normal distribution, a mean differ-
ence of 500 ml within the first 24 h was estimated as a rele-
vant increase in postoperative mediastinal blood loss, which
could be detected by a sample size of 60 patients assuming a
standard deviation of 500 ml in both groups using an
unpaired t-test (a¼0.05 and b¼0.8).
Results are presented as median (inter-quartile range) or
numbers (percentage) and compared by the x2 test or
Mann–Whitney U-test. Due to the right-skewed distribution
of postoperative blood loss, we modelled the blood loss
after 6 and 24 h in a log-linear regression model with five
prespecified covariates without any model selection. Loss
of the largest vWF multimers, gender, and increased bleed-
ing risk were inserted as dichotomous variables, whereas
age (per 10 yr increase) and COL test values (per 10 U
increase) were entered into the model as continuous vari-
ables. Sensitivity analyses were performed excluding subjects
with transapical valve replacement or patients with FFP
transfusion to investigate the changes of the covariate
estimates and confidence intervals (CIs). All analyses and
graphs were performed using Intercooled Stata version
11.0 for Macintosh (StataCorp, College Station, TX, USA).
Results
Baseline biological and surgical data
Of the 60 subjects included in the study, 48 (80%) showed
altered vWF multimer structure evident by the loss of the
largest vWF multimers before operation. Baseline data were
similar in both groups (Table 1). INR values were ,1.5 in
each patient, and aPTT values were within the normal
range in all but one subject with the altered multimer
structure.
Three subjects (aged 76–84 yr) with redo-cardiac surgery
(EuroSCORE22 range 11–17) were treated with transapical
valve replacement not requiring CPB. In the remaining 57
subjects (EuroSCORE range 2–11), aortic valve replacement
was performed with the use of CPB.
Bleeding history
Before operation, one subject with loss of the largest vWF
multimers and clopidogrel treatment reported frequent
nose bleeds. Two other subjects reported increased bleeding
during previous surgery, one of them with the altered vWF
multimer structure.
Perioperative bleeding and transfusion of blood
products
One subject underwent surgical re-exploration within 2 h
after valve replacement due to massive bleeding from an
arterial vessel in the mediastinum and was excluded from
further analysis regarding postoperative bleeding and trans-
fusion. Blood loss from mediastinal drainage after 6 h was
250 ml (105–400) in the group with altered vWF multimers
and 145 ml (85–240) in the group with normal multimers
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(P¼0.182). After 24 h, the cumulative loss was 495 (270–
650) and 375 (310–600) ml in the group with altered and
normal multimer structures, respectively (P¼0.713; Fig. 2).
Multivariable analysis showed a weak tendency to increased
postoperative bleeding in the group with the altered multi-
mer structure (1.55-fold increase; 95% CI: 0.84–2.82;
P¼0.153), which disappeared completely after 24 h
(Table 2). The sensitivity analyses excluding subjects with
FFP transfusions or with transapical valve replacement did
not reveal relevantly changed point estimates or CI (data
not shown). The incidence of major bleeding defined as
.1000 ml within 24 h was similar in both groups (11%
and 8% in subjects with altered and normal multimers,
respectively).
During surgery and the first 24 h, red blood cell concentrates
were administered in 23 (49%) and 9 (75%) of the subjects
with altered and normal vWF multimers, respectively. In sub-
jects with altered vWF multimers, three subjects (6%) received
platelet concentrates and seven patients (15%) received FFP.
In subjects with the normal vWF structure, no platelet
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Fig 2 Scatter plot of postoperative bleeding volumes. Subjects with preoperative loss of the largest vWF multimers are marked with blue
hollow circles, and subjects with normal vWF multimers are marked with green filled circles. Dashed and straight lines are lowess smothers
(i.e. a non-linear regression line) in each group.
Table 1 Subject characteristics. Data are numbers (%) or median (inter-quartile range). AV, aortic valve; aPTT, activated partial thromboplastin
time; INR, international normalized ratio; vWF, von Willebrand factor. *Exact values of mean gradient and orifice area were only present in 56
and 46 subjects, respectively. †Measurements for aPTT and fibrinogen were only available in 59 and 58 subjects, respectively
All subjects (n560) Altered vWF multimer structure (n548) Normal vWF multimer structure (n512)
Male gender 33 (55%) 25 (52%) 8 (67%)
Age (yr) 74 (67–80) 75 (66–81) 73 (68–80)
EuroSCORE22 6 (5–8) 7 (5–8) 6 (5–7)
Blood group O 23 (38%) 17 (35%) 6 (50%)
Mean gradient AV (mm Hg)* 49 (40–56) 50 (40–58) 43 (41–51)
Orifice area AV (cm2)* 0.71 (0.60–0.80) 0.70 (0.60–0.80) 0.75 (0.67–0.90)
Aspirin intake 29 (48%) 26 (54%) 3 (25%)
Clopidogrel intake 2 (3%) 2 (4%) 0 (0%)
Haemoglobin (g litre21) 133 (123–144) 134 (124–146) 132 (117–141)
Creatinine (mmol litre21) 80 (71–103) 79 (71–101) 90 (75–108)
Platelet count (×109 litre21) 248 (194–267) 248 (190–265) 242 (204–344)
INR 1.0 (0.9–1.1) 1.0 (0.9–1.1) 1.0 (0.9–1.1)
aPTT (s)† 29 (27–31) 29 (27–32) 28 (27–29)
Fibrinogen (g litre21)† 3.2 (2.7–3.6) 3.2 (2.7–3.6) 3.1 (2.8–3.8)
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concentrates or FFP were used. The fibrinogen concentrate
was administered in 14 subjects (30%) with altered vWF multi-
mers and in two subjects (17%) with normal multimers. There
was no difference in the percentage of subjects requiring blood
or haemostatic products or in haemoglobin levels, platelet
counts, fibrinogen levels, and classical coagulation para-
meters in the measurements before, directly after surgery,
and on the first postoperative day. No subjects received
desmopressin during the hospital stay.
Perioperative vWF levels and multimer structure
There was no relevant difference in preoperative measure-
ments of vWF:Ag and vWF:CB (Fig. 3). Preoperative vWF:Ag
and vWF:CB were normal (i.e. ≥50 IU dl21) in all but one
subject who also showed loss of the largest vWF multimers.
In the postoperative measurement, vWF:Ag and vWF:CB
were normal in all subjects and were about twice as high
compared with the preoperative values (Fig. 3). The
vWF:CB/vWF:Ag ratio9 23 was similar in subjects with loss of
the largest multimers before and after operation (Fig. 3).
There was no obvious difference in perioperative vWF para-
meters in subjects with and without FFP transfusion (Table 3).
In the vWF multimer analysis on the first postoperative day,
the largest vWF multimers were present in all subjects. The
percentage of large vWF multimers was 21 (18–24)% before
and 34 (30–39)% after surgery in the group with the altered
multimer structure and 26 (25–28)% before and 39 (32–
42)% after surgery in the group with the normal multimer
structure, respectively. This resulted in a per cent increase of
61 (39–86)% and 45 (17–60)% in subjects with and without
loss of the largest multimers, respectively.
Perioperative platelet activity
The median perioperative platelet activity, as evaluated by
TRAP, COL, and RISTO tests, was slightly lower in subjects
with loss of the largest vWF multimers (Table 4). Before oper-
ation, 22 subjects (37%) showed AUCTRAP values ,71 U,
which is the lower normal range for these patients.21 In 20
of these subjects (91%), the largest vWF multimers were
missing. On the first postoperative day, TRAP test values
decreased, while COL and RISTO test values were comparable
with preoperative measurements (Table 4). In the multivari-
able analysis, low AUCCOL values were not associated with
increased postoperative bleeding (Table 2).
Follow-up
A laboratory follow-up was performed in 47 subjects (78%)
after a median period of 56 days (43–88). Thirteen subjects
or their general practitioners abstained from sending blood
samples or sent blood samples that could not be analysed.
The largest vWF multimers were missing in four (8%) of the
analysed blood samples, but vWF:Ag and vWF:CB were .50
IU dl21 and the vWF:CB/vWF:Ag ratio was ≥0.7 in all subjects.
Discussion
We found that the preoperative loss of high-molecular-weight
vWF multimers in subjects undergoing aortic valve replace-
ment due to severe stenosis did not affect early (6 h) and
late (24 h) postoperative mediastinal blood loss. This finding
might be explained by perioperative release of vWF and rapid
recovery of the largest multimers. Our study is, therefore, in
agreement with two recently published studies including a
total of 86 patients with severe aortic stenosis which found
no association of the altered vWF multimer structure before
operation and increased bleeding within 24 h after aortic
valve replacement.10 11 However, neither of these studies eval-
uated the influence on early blood loss and the effect of FFP
transfusion containing vWF.
vWF is an acute-phase protein, which is released together
with FVIII from the endothelium during major surgery.9
Table 2 Univariate and multivariable log-linear regression analysis for mediastinal blood loss 6 and 24 h after surgery (n¼59). Exponentiated
coefficients are given to simplify the interpretation. For example, a factor of 2 would indicate a blood loss twice as high in subjects with the
specific characteristic as those without the specific characteristic. One subject was excluded from analysis due to surgical bleeding requiring
revision
Univariate analysis Multivariable analysis
eb (95% CI) P-value eb (95% CI) P-value
6 h
Altered vWF multimers 1.52 (0.87–2.65) 0.141 1.55 (0.84–2.82) 0.153
AUCCOL (per 10 U) 0.92 (0.84–1.02) 0.116 0.98 (0.86–1.10) 0.685
Increased bleeding risk 1.42 (0.63–3.22) 0.396 1.40 (0.61–3.19) 0.417
Age (per 10 yr) 1.17 (0.89–1.55) 0.253 1.18 (0.85–1.64) 0.312
Female gender 0.87 (0.55–1.37) 0.533 0.81 (0.50–1.31) 0.389
24 h
Altered vWF multimers 1.05 (0.69–1.59) 0.834 1.05 (0.66–1.66) 0.837
AUCCOL (per 10 U) 0.97 (0.90–1.04) 0.341 0.98 (0.90–1.08) 0.705
Increased bleeding risk 1.44 (0.79–2.62) 0.234 1.41 (0.75–2.64) 0.275
Age (per 10 yr) 1.06 (0.86–1.30) 0.601 1.05 (0.82–1.35) 0.680
Female gender 0.88 (0.63–1.23) 0.447 0.88 (0.61–1.26) 0.457
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Previous studies in patients undergoing cardiac surgery
demonstrated that vWF antigen level and vWF ristocetin
cofactor (vWF:RCo) activity before and directly after surgery
were comparable but increased within 24 h after surgery to
about 200–300 IU dl21,9 24 25 which is in agreement with
our data. In contrast, metalloprotease ADAMTS13, which is
responsible for degradation of vWF,4 was relatively low
after operation probably due to haemodilution.24 Elevated
vWF activity persisted for several days.8 11 24 However, the
minimal or optimal amount of vWF for adequate haemo-
stasis after cardiac surgery is not known. The largest vWF
multimers recovered within the first hours after cardiac
surgery8 or even within the time of surgery in 12 of the 14
patients undergoing aortic valve surgery.9 In agreement,
the largest multimers were present in all of our subjects in
the postoperative measurements. In addition, we found
that a perioperative increase in large vWF multimers was
more evident in the group with the altered multimer struc-
ture. A potential influence of altered vWF multimers before
operation on early but not late postoperative bleeding
seems reasonable and important, as most haemostatic prod-
ucts are transfused early after surgery. We found that
the altered multimer structure had a small, not statistically
significant, effect on increased blood loss after 6 h
(1.55-fold increase; 95% CI: 0.84–2.82; P¼0.153), which
was not evident after 24 h. FFP transfusion had no obvious
effect on postoperative vWF levels and multimers. However,
plasma was likely to be transfused in subjects with increased
bleeding, creating a potential increase in vWF. Accordingly,
the influence of the substitution of vWF by plasma transfu-
sion might remain undetected in our study.
Table 4 Platelet aggregometry measurements. Data are median
(inter-quartile range) of area under the curve (AUC) values.
Postoperative data were available in 59 patients (47 patients with
altered vWF multimers) for the TRAP and COL tests and in 58
patients (47 with altered vWF multimers and 11 with normal vWF
multimers) for the RISTO test
All subjects
(n560)
Altered vWF
multimer
structure (n548)
Normal vWF
multimer
structure (n512)
AUCTRAP (U)
Preop 86 (62–97) 80 (60–94) 94 (86–99)
Postop 45 (35–62) 42 (34–59) 53 (40–67)
AUCCOL (U)
Preop 41 (23–60) 36 (23–51) 62 (30–72)
Postop 34 (22–51) 32 (22–49) 45 (23–70)
AUCRISTO (U)
Preop 49 (30–84) 45 (30–75) 69 (30–122)
Postop 43 (28–68) 41 (26–68) 56 (37–77)
Table 3 Influence of plasma transfusion on vWF measurements
in subjects with the altered vWF multimer structure. Data are
number (proportion) or median (inter-quartile range). Altered
vWF multimer structure normalized within 24 h in all subjects
Parameter Time
point
No FFP
transfusion
(n541)
With FFP
transfusion (n57)
vW:Ag Preop 124 (100–145) 136 (112–166)
Postop 214 (182–249) 215 (194–254)
vW:CB Preop 115 (93–137) 125 (90–135)
Postop 239 (188–301) 215 (195–262)
vW:CB/
vW:Ag ratio
Preop 0.94 (0.86–1.03) 0.85 (0.70–0.99)
Postop 1.11 (1.03–1.18) 1.03 (0.92–1.18)
Large
multimers
(%)
Preop 21 (18–25) 22 (21–22)
Postop 35 (30–40) 29 (21–33)
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Fig 3 (A–C) Box-whisker plots of vWF antigen (vWF:Ag) activity (in
IU dl21), vWF collagen-binding (vWF:CB) activity (in IU dl21), and
their ratio before surgery, on the first morning after surgery, and
at follow-up. Subjects with preoperative loss of the largest vWF
multimers are marked in blue, and subjects with the normal mul-
timer structure are marked in green.
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The prevalence of altered vWF multimer structure similar
to vWD type 2A in patients with severe aortic stenosis is
still under debate. Depending on the method and diagnosis
criteria, the prevalence of altered multimer structure
similar to vWD type 2A has been reported to be between
0% and 90% in patients with severe aortic stenosis.8 9 11 26 27
Aside from the loss of the largest vWF multimers, additional
changes such as increases in low and intermediate vWF mul-
timers due to degradation by ADAMTS13 are required for the
diagnosis of vWD type 2A.11 The altered multimer structure
in patients with severe aortic stenosis should, therefore,
not be referred to as vWD type 2A.
We found that vWF:Ag, vWF:CB, and vWF:CB/vWF:Ag ratios
before and after surgery were similar in subjects with the
altered and normal multimer structures, which is in agree-
ment with a former study.10 Preoperative vWF:Ag or
vWF:CB levels were below the normal range (i.e. ,50 IU
dl21) and aPTT was prolonged in one subject only. In
former studies, loss of high-molecular-weight vWF multimers
has been frequently associated with haemorrhagic disorders
such as gastrointestinal bleeding, epistaxis or increased
bleeding after dental procedures.2 7 8 In agreement with
previous studies showing haemorrhagic disorders in 0–26%
of the patients with severe aortic stenosis,8 9 11 5% of
our subjects reported a haemorrhagic diathesis. Previous
reports in patients with vWD type 2A also reported that clin-
ical manifestations were often subtle, and severe bleeding
was rare.23 28 In the multivariable analyses, we did not find
increased bleeding in subjects with haemorrhagic disorders,
but the small number of subjects does not allow definite con-
clusions. Our findings are, therefore, in agreement with a
recent study,11 whereas the former study by Vincentelli and
colleagues8 reported increased bleeding in patients with
haemorrhagic diathesis.
Several studies have previously described impaired
platelet function in a large proportion of patients with
severe aortic stenosis.5 8 12 13 In these studies, different
platelet function analysers were used including PFA-100,
the cone and plat(elet) analyser, P-selectin expression on
platelet surface, and shear-induced platelet aggregation.
Impaired platelet activity in patients with severe aortic sten-
osis has been attributed not only to high shear stress
damage14 but also to selective deficiency of the largest
vWF multimers.5 12 In the present study, we used multiple
electrode aggregometry for the first time in these patients.
Preoperative testing revealed median AUCTRAP values of 86
(62–97) U. These values are substantially lower than the
mean (SD) AUCTRAP values 101 (20) U reported in patients
undergoing coronary artery bypass graft surgery.21 The
proportion of patients with AUCTRAP below the normal
range was significantly higher in patients with aortic sten-
osis than in patients undergoing bypass surgery (37% vs
5%). Our finding is, therefore, in agreement with previous
studies reporting that 50–92% of the patients with severe
aortic stenosis have impaired platelet function depending
on the analysis method. However, lower test values from
multiple electrode aggregometry were not associated with
increased postoperative bleeding in our multivariable
analysis. This is in agreement with recent data in paediatric
cardiac patients.29 A recent study showed that the RISTO
test can identify patients with vWD type 1.30 We found no
difference between subjects with the altered and normal
multimer structures using this test. We speculate that the
RISTO test depends on vWF concentrations that are low in
vWD type 1, but were normal in all but one of our subjects.
Values of multiple electrode aggregometry strongly depend
on platelet count,21 leading to lower postoperative TRAP
values. Remarkably, RISTO test values were not obviously
lowered, potentially due to increased vWF concentration
after surgery.
Most patients with loss of the largest vWF multimers show
sustained corrections of clinical and biological haemostatic
abnormalities after aortic valve replacement.5 8 However,
previous studies have found the recurrence of the altered
multimer structure after a few months in up to 5% of the
patients.5 8 Similarly, four of our subjects (8%) showed a rela-
tive loss of the largest multimers after a median follow-up of
56 days. Residual flow disturbances could be responsible for
recurrent loss of the largest multimers.8
Our study has some limitations: first, we cannot exclude
that small differences in postoperative bleeding volumes
and clinically more relevant outcomes, such as transfusions
of blood products or incidence of major bleeding, might
have become significant with a larger sample size. In fact,
our sample size calculation did not match well with the
actual findings, resulting in the need for us to adapt our stat-
istical analysis. We do not think that this has influenced the
interpretation of our data or the clinical relevance of our
results. Secondly, vWF levels31 and multiple electrode aggre-
gometry21 show fluctuations and variation, which might
have influenced our study results. Thirdly, strict application
of institutional guidelines for transfusion of blood and
haemostatic products was not enforced by the investigators
in this observational study. Finally, our results might not be
directly transferred to patients with other cardiac conditions
associated with loss of the largest vWF multimers5 8 32 33 or
to patients undergoing major non-cardiac surgery, that is,
when the aortic stenosis persists.
In conclusion, the altered vWF multimer structure and
reduced platelet function are common in patients with
severe aortic stenosis but had no relevant effect on post-
operative bleeding after aortic valve replacement probably
due to rapid correction of multimer structure and vWF
release during the perioperative period. In asymptomatic
patients undergoing aortic valve replacement, vWF levels
and multimers need not be checked before operation.
Based on our findings, coagulopathy after aortic valve
replacement might not be explained by the lack of the
largest vWF multimers. Accordingly, treatment options
aiming to restore vWF (e.g. desmopressin13 and vWF concen-
trate)9 might not be useful, and other causes of post-
operative coagulopathy such as low levels of fibrinogen,34
35 impaired thrombin generation, heparin rebound, and inhi-
bitors of platelet aggregation17 18 must be excluded.
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